Physician profile
Sameer Sofat
NPI 1083614903
$2,275.83
in general payments reported to CMS, 2019-2025
26 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $90.10 · 2021: $20.68 · 2022: $319 · 2023: $359 · 2024: $312 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $423.34 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $328.13 | 2019-2023 | Repatha |
| Pfizer INC. | $298.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $262.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $200.38 | 2022-2024 | Verquvo |
| Boston Scientific Corporation | $121.50 | 2019-2024 | Watchman |
| Regeneron Healthcare Solutions, INC. | $87.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $59.09 | 2019-2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $57.40 | 2019 | |
| Amarin Pharma, INC. | $44.77 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.75 | 2023 | Lifevest |
| Atricure, INC. | $26.45 | 2022 | |
| Abbott Laboratories | $24.97 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $23.60 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $22.71 | 2023 | Assure Wcd |
| Astellas Pharma US INC | $20.94 | 2019 | |
| Esperion Therapeutics, INC. | $20.68 | 2021 | |
| Philips North America LLC | $19.86 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $19.51 | 2023 | Inpefa |
| Medtronic Vascular, INC. | $19.13 | 2019 | |
| Edwards Lifesciences Corporation | $18.84 | 2019 | |
| Bardy Diagnostics, INC. | $17.81 | 2020 | |
| Lundbeck LLC | $15.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.20 | 2019 | |
| Gilead Sciences, INC. | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Sofat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.